AbbVie announced the company’s latest chimeric antigen receptor (CAR)-T cell investment, a collaboration with Caribou Biosciences worth $40 million up front in cash and equity to develop two CRISPR-edited cell therapies against AbbVie-specified targets.
At the 2021 virtual JP Morgan Healthcare Conference, Vertex Pharmaceuticals’ chief executive officer Reshma Kewalramani said the company is looking to buy “mid- and late-stage assets.”
BioSpace presented the NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5 with numerous presentations, abstracts and posters.
Paris-based Ipsen secured Fast Track designation from the U.S. Food and Drug Administration for Onivyde (irinotecan liposome injection) for study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen.
BioSpace reviews whose wallets got thicker in the biopharma industry, from largest to smallest, during the Nov. 11-17 period
Clarivate Plc released the company’s list of Highly Cited Researchers 2020 that identifies researchers who “demonstrated significant influence in their chosen field or fields through the publication of multiple highly cited papers during the last decade.”
Two new companies backed by significant financing that will be used to develop treatments for a wide range of diseases launched: Metagenomi will concentrate on next-generation gene therapies and Kira Pharmaceuticals will tackle complement-mediated diseases.
Intent on growing PerkinElmer’s life sciences portfolio, the company agreed to acquire cell engineering specialist Horizon Discovery Group for $383 million.
The Nobel Prize in Chemistry was awarded to Emmanuelle Charpentier and Jennifer A. Doudna for their discovery and development of CRISPR gene editing.
